Contribute Try STAT+ Today

Translating the promise of cancer genomics into health equity has not yet become a reality, two experts write in a commentary published recently in Cancer Cell. Instead, the racial gaps in cancer mortality have only slightly narrowed since the human genome was sequenced two decades ago, they note, and in preventable cancers such as breast and colorectal cancer, socioeconomic inequalities in cancer deaths are widening.

DNA data are certainly being used to precisely target cancer and other diseases with treatments developed to block genetic variants that give rise to malignancy. But that remarkable precision depends on the populations whose genetic sequences have been deciphered. For the most part, existing genetic data comes from people of European ancestry. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.